AI-assisted research analysis by FutureKnowledge. Sources checked 27 October 2026. This is not investment advice.
Reviewed by FutureKnowledge: figures, dates and attributions were checked against the linked sources before publication.
Cipla’s Q2 FY27 net profit fell 35% to ₹878 crore as North America sales dropped 19%, the drugmaker said on Tuesday, while its India business posted record quarterly sales. Revenue slipped 2% to ₹7,404 crore and the EBITDA margin narrowed to 18.7% from 25% a year ago, according to the company’s results press release filed with the NSE.
The key question for investors and the wider Indian pharma sector is how quickly new US launches can replace income lost from older, high-margin generics.
Cipla Q2 results: the key numbers
| Metric (consolidated) | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Revenue from operations | ₹7,404 crore | ₹7,589 crore | -2% |
| EBITDA | ₹1,388 crore | ₹1,895 crore | -27% |
| EBITDA margin | 18.7% | 25.0% | -630 bps |
| Profit attributable to shareholders | ₹878 crore | ₹1,351 crore | -35% |
| Basic EPS | ₹10.86 | ₹16.73 | -35% |
Some reports give net profit as ₹851.51 crore, a 37% fall. Both figures are correct but measure different things. The financial results filing shows ₹851.51 crore as total profit for the period and ₹877.54 crore as the share attributable to Cipla’s owners, after a ₹26 crore loss at subsidiaries with minority holders. The Free Press Journal used the first figure, while the company and most outlets used the second. This article uses the attributable figure.
Profit came in below the roughly ₹942 crore analysts had expected, Whalesbook reported. Cipla’s half-year profit attributable to shareholders was ₹1,667 crore, down from ₹2,649 crore in the first half of FY26, the filing shows.
What happened in each business
The segment split in the press release shows where the pressure came from:
- One India: ₹3,516 crore, up 12% from ₹3,146 crore, Cipla’s highest quarterly India sales. The company said its branded prescription business grew 15%. It also said trade generics grew at a strong double-digit rate from the previous quarter, helped by more than 15 launches.
- North America: ₹1,643 crore, down 19% from ₹2,039 crore. In dollars, US sales were $172 million, up $10 million from the June quarter.
- One Africa: ₹1,171 crore, down 1%. South Africa fell 3% to ₹872 crore, although private-market secondary sales grew 6.5% against market growth of 5%.
- Emerging markets and Europe: flat at ₹967 crore, or $101 million.
- API and others: ₹107 crore, down 59% from ₹259 crore.
India now makes up about 48% of revenue and North America about 22%, according to a summary of the investor presentation.
Why Cipla’s profit fell
Cipla’s release does not explain the North America decline. The context comes from earlier quarters. A year ago, North America sales were $233 million. At the time, management said revenue from generic Revlimid, a cancer drug copy that earned high margins during a limited-competition period, was being phased out, with the full impact expected over the following quarters, Business Standard reported. Whalesbook also pointed to softer demand for the drug and pricing pressure in US generics.
The fall in profit was larger than the fall in revenue because the lost US sales carried high margins. India’s growth is real, but it comes at lower margins and cannot fully replace that income. The same pattern showed up in the June quarter, when profit fell 39% to ₹789 crore, the EBITDA margin was 16.7% and US sales were $162 million, IIFL reported.
Seen that way, the September quarter shows early recovery from a low base: revenue up 4% from the previous quarter and the margin up 200 basis points, as MD and Global CEO Achin Gupta pointed out in the release. He said the North America outlook is supported by the company’s “upcoming product pipeline”. The pipeline includes US approval for a generic of the Advair Diskus inhaler, Cipla’s first dry-powder inhaler approval from its US manufacturing network. It also includes an exclusive partnership with China’s Qilu Pharmaceutical to sell a biosimilar of Merck’s cancer drug Keytruda in the US. Cipla’s albuterol inhaler holds a 22% share of the US albuterol inhaler market, the release says.
How Cipla shares reacted
The stock was weak but did not collapse. The Economic Times reported that shares fell about 3% to an intraday low of ₹1,320 and traded at ₹1,323.70, down 2.3%, around 1:48 pm. That left the stock down about 12% so far in 2026. IANS reported a smaller decline of 0.6% at ₹1,347 later in the afternoon.
What it means for India’s pharma sector
Cipla’s results show a pattern across Indian generic exporters. The US remains the biggest profit pool, but individual high-margin products come and go as more competitors enter. Companies whose US earnings rely on a small number of limited-competition products tend to see sharper profit swings when those products face competition. Firms with large domestic branded businesses have steadier earnings, although the margins are usually lower.
The other side of the same trend showed up in Novartis’s third-quarter results, where generic competition cut Entresto sales by 38%. Patent expiries create openings for Indian manufacturers, but profits from any single launch tend to fade.
Exposure varies by business model:
- More exposed: companies with concentrated US generic portfolios, especially where a few products drive a large share of profit.
- Less exposed: companies with large India branded franchises, steady chronic-therapy portfolios and net cash. Cipla reported net cash of ₹9,823 crore.
Scenarios to watch
The table below shows conditional scenarios, not predictions.
| If… | Then a likely consequence is… |
|---|---|
| gAdvair and other inhaler launches gain US share over the next few quarters | North America dollar sales could keep rising from the $162-172 million range and support margins |
| US generic pricing pressure deepens | Sequential margin gains could stall even with India growing at double digits |
| India keeps growing at 12% or more | The domestic business would cushion profits but, at lower margins, would not fully replace the lost US income |
| The Keytruda biosimilar programme is delayed | The medium-term US growth story would rely more on respiratory and peptide products |
What to watch next
- Management comments on the earnings call about FY27 margins and the timing of US launches.
- Results from US FDA inspections at Cipla’s InvaGen sites in New York, disclosed to exchanges in August and October.
- Q2 results from other large Indian drugmakers this earnings season, which will show whether US weakness is specific to Cipla or affects the whole sector. Our earlier coverage of Infosys’ Q2 results showed a similar US-demand theme in IT services.
Bottom line
Record India sales and a better quarter-on-quarter margin are encouraging, but a 19% fall in North America revenue still drove profit down 35% from a year ago. The coming quarters will show whether new inhaler and biosimilar launches can rebuild the US business.
Method note: This analysis compared Cipla’s NSE-filed press release and financial results with reporting from The Economic Times (via inkl), IANS, The Free Press Journal, IIFL, Business Standard, Whalesbook and an investor-presentation summary by Investywise. The different net-profit figures were resolved using the company’s filing. Intraday share prices differ by source and time and are attributed separately.